Vertis, a precision medical technology company based on proteomics, announced on the 2nd that it will participate in 'BIO KOREA 2025' held at COEX in Seoul for three days starting on the 7th and introduce its mass spectrometry-based omics analysis service 'PASS'.
Bio Korea, which is celebrating its 20th anniversary this year, is Korea’s largest biohealth exhibition and conference jointly hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do Province. It has established itself as a place where global health industry experts share the latest industry technology trends and seek global cooperation and business opportunities. During the event, Vertis will operate a promotional booth at the exhibition hall and provide introductions and consultations on customized proteome analysis services to domestic and international practitioners and R&D personnel.
PASS is an omics analysis solution that integrates mass spectrometry-based proteome analysis and bioinformatics data analysis capabilities, and provides various analysis services necessary for basic research and new drug R&D in the pharmaceutical and bio fields. Recently, studies utilizing PASS have achieved results such as publication of academic journal papers and approval of clinical trial plans, and its analysis data quality and customized consulting capabilities are being recognized. In particular, a study on the treatment of acute liver failure using exosome therapeutics was published in Nature Communications in February, and a study on promoting bone regeneration based on PROTAC (PROteolysis-Targeting Chimera) was published in Advanced Science in March. Then, in April, SNI Bio's exosome-based acute cerebral infarction treatment, which performed protein characterization and quality evaluation, received approval for a phase 1 clinical trial plan from the Ministry of Food and Drug Safety for the first time in Korea.
Park Sung-joon, the director of the PASS Center, said, “Through our participation in Bio Korea, we hope to inform those involved in basic research and new drug R&D at home and abroad of PASS’s analytical capabilities and achievements, and expand opportunities to provide services.” He added, “We will continue to do our best to successfully carry out projects based on advanced analytical technologies and customer-tailored consulting capabilities, and to grow together as a key partner in the pharmaceutical and bio fields.”
Meanwhile, Vertis will provide detailed consultation on the PASS service at booth F19 in Hall C of COEX.
- See more related articles
You must be logged in to post a comment.